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TRANSLATIONAL RELEVANCE  
Breast cancers in women with germline-mutated BRCA1/2 (gBRCAm) are sensitive to 
platinum chemotherapy and to poly(ADP-ribose) polymerase (PARP) inhibitors, which target 
an underlying defect in DNA repair. Niraparib is a potent oral selective PARP inhibitor, with 
demonstrated efficacy in ovarian and prostate cancers. The BRAVO trial was designed to 
compare the PFS of patients treated with either niraparib monotherapy or commonly used 
mono-chemotherapy regimens for advanced/metastatic HER2-negative breast cancer in 
gBRCAm-carriers, irrespective of the tumor hormonal status. The trial was stopped early due 
to futility and informative censoring in the control arm, and so unable to assess its primary 
endpoint. However, the objective response rate of 35% in the niraparib arm confirmed the 
drug’s activity in this heavily pre-treated patient population, and thus supports the role of 
PARP inhibitors in the treatment of breast cancer and suggests that niraparib should be 
further explored in patients with breast cancer and gBRCAm. 
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Purpose To investigate the activity of niraparib in patients with germline-mutated 
BRCA1/2 (gBRCAm) advanced breast cancer (aBC).  
Patients and methods BRAVO was a randomized, open-label phase 3 trial. Eligible 
patients had gBRCAm and HER2-negative aBC previously treated with ≤2 prior lines of 
chemotherapy for aBC or had relapsed within 12 months of adjuvant chemotherapy, and 
were randomised 2:1 between niraparib and physician’s choice chemotherapy (PC) 
(monotherapy with eribulin, capecitabine, vinorelbine, or gemcitabine). Patients with 
hormone-receptor positive tumours had to have received ≥1 line of endocrine therapy and 
progressed during this treatment in the metastatic setting or relapsed within one year of 
neo/adjuvant treatment.  The primary endpoint was centrally-assessed progression-free 
survival (PFS). Secondary endpoints included overall survival (OS), PFS by local 
assessment, objective response rate (ORR), and safety.  
Results After the pre-planned interim analysis, recruitment was halted based on 
futility, noting a high degree of discordance between local and central PFS assessment in 
the PC arm that resulted in informative censoring. At the final analysis (median follow-up: 
19.9 months), median centrally-assessed PFS was 4.1 months in the niraparib arm (n=141) 
versus 3.1 months in the PC arm (n=74; hazard ratio [HR] 0.96; 95% CI: 0.65-1.44; P=0.86). 
HRs for OS and local-PFS were 0.95 (95% CI 0.63-1.42) and 0.65 (0.46-0.93), respectively.  
ORR was 35% (95% CI 26-45) with niraparib and 31% (19-46) in the PC arm. 
Conclusion Informative censoring in the control arm prevented accurate assessment of 
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BRCA1 and BRCA2 encode two proteins that play a central role in the DNA damage 
response, especially in the repair of double-strand breaks (DSB) by homologous 
recombination repair (HRR) and the protection of the stalled replication fork. Tumors from 
patients with a BRCA1/2 germline mutation (gBRCAmut) are likely to have impaired HRR 
and therefore may be more vulnerable to some types of DNA damaging agents1. Poly (ADP-
ribose) polymerase (PARP) inhibitors are selectively cytotoxic for these tumor cells mainly 
because they inhibit the enzymatic activity of PARP (which recruits DNA damage repair 
proteins), also trapping PARP-1 to DNA, resulting in a stalled replication fork, DNA damage, 
and ultimately cell death2.  
Niraparib is a potent oral, selective PARP-1 and PARP-2 inhibitor with half maximum 
inhibitory concentrations (IC50) of 3.8 nmol/L and 2.1 nmol/l, respectively, which also has 
potent PARP trapping activity2,3. Niraparib has demonstrated selective anti-proliferative 
activity in cancer cell lines that have been silenced for BRCA1/2 or carry BRCA1/2 mutations 
compared to their wild type counterparts. In contrast, niraparib has demonstrated weak 
activity in normal human cells4. In a Phase I trial, the maximum tolerated dose was 
established at 300mg/day in cohorts enriched for BRCA1/2 germline mutation carriers, 
sporadic platinum-resistant high-grade ovarian cancer, and sporadic prostate cancer5. Dose-
limiting toxic effects reported in the first cycle were grade 3 fatigue (one patient given 30 
mg/day), grade 3 pneumonitis (one given 60 mg/day), and grade 4 thrombocytopenia (two 
given 400 mg/day). Promising antitumor activity was observed among BRCA1/2 mutation 
carriers with ovarian cancer and breast cancer, with partial responses in eight of 20 (40%) 
and two of four (50%), respectively.  In the phase III NOVA trial, niraparib was compared 
with placebo as maintenance treatment for patients with platinum-sensitive, recurrent 
ovarian cancer6. Niraparib showed superiority in terms of progression-free survival (PFS) 
versus placebo in all groups of patients, although the magnitude of the clinical benefit 
differed according to the presence of a germline BRCA1/2 mutation or the HRR status of the 
tumor. Patients in the niraparib group had a significantly longer median duration of PFS than 
did those in the placebo group, including 21.0 vs. 5.5 months in the gBRCAmut cohort, as 
compared with 12.9 months vs. 3.8 months in the non-gBRCAmut cohort for patients who 
had tumors with homologous recombination deficiency (HRD) and 9.3 months vs. 3.9 
months in the overall non-gBRCAmut cohort. The most common grade 3 or 4 adverse 
events that were reported in the niraparib group were thrombocytopenia (in 33.8%), anemia 
(in 25.3%), and neutropenia (in 19.6%), which were managed with dose modifications. 
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The BRAVO trial was a phase III randomized, open label, multi-center, controlled study that 
was designed to compare the efficacy and safety of niraparib to  commonly utilized 
chemotherapy regimens considered to be standard of care at the time of study initiation and 
enrolment (capecitabine, eribulin, vinorelbine or gemcitabine) for the treatment of 
advanced/metastatic HER2-negative breast cancer in BRCA1/2 germline mutation carriers, 
irrespective of the tumor hormonal status.  
In March 2017, the independent data monitoring committee (IDMC) reviewed a planned 
interim efficacy analysis for futility and determined that the study should be stopped due to 
the PFS analysis results crossing the pre-defined boundary, noting a high degree of 
discordance between local and central PFS assessments that resulted in informative 
censoring. As a consequence, enrolment was stopped on 29 March 2017. Here, we report 




Eligible patients were at least 18 years old, had confirmed HER2-negative metastatic or 
locally advanced breast cancer that was not amenable to local treatment with curative intent, 
and had a deleterious or suspected deleterious germline BRCA1/2 mutation detected by 
local or central testing with the validated, sequencing-based BRACAnalysis® test (Myriad 
Genetics). Central confirmation of BRCA status was performed at any time prior to 
randomization for all patients regardless of whether they were enrolled based on either a 
previous Myriad test or a local test. A whole blood sample was centrally tested by 
certified Myriad Genetics Laboratories in Salt Lake City, Utah, USA. If after inclusion, a 
patient turned out not to have a germline BRCA mutation per central laboratory results, 
the patient could still continue on study at his/her physician’s discretion and according to 
the patient’s preference. 
To be considered eligible, patients had to have received <2 prior cytotoxic regimens for 
advanced or metastatic breast cancer. Those not having received prior cytotoxic regimens in 
this setting were allowed to enter the study only if they had relapsed during or within 12 
months of (neo-) adjuvant cytotoxic therapy. Prior therapy should have included a taxane 
and/or anthracycline (unless contraindicated). Patients with hormone-receptor positive 
breast cancer had to have hormone-resistant disease, defined either as having relapsed 
while receiving adjuvant endocrine therapy or within one year of its completion, or having 
progressed while receiving endocrine therapy in the metastatic setting. Previous 
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neoadjuvant or adjuvant platinum-based chemotherapy was permitted if the patient had 
relapsed 12 months or more after the last dose of platinum. Previous treatment with platinum 
for metastatic disease was allowed if the patient had not progressed while on treatment and 
subsequent progression occurred after 8 weeks from the last administration of platinum. 
Patients had to have measurable disease according to Response Evaluation Criteria in Solid 
Tumors (RECIST) version 1.17 or clinically evaluable non-measurable disease, with 
evidence of disease progression within 3 months prior to enrolment without change of 
therapy; an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 
2; and adequate bone marrow, hepatic, and renal function.  Bone-only disease with at least 
one lytic component was allowed. Patients with central nervous system (CNS) metastases 
were eligible provided they had completed local treatment at least one month prior to 
enrolment, had no new or progressive signs or symptoms related to CNS disease, and were 
off steroids for at least two weeks. 
Trial design 
The BRAVO study was an open-label, randomized, multicenter, controlled phase III trial 
comparing the efficacy and safety of niraparib versus physician’s choice of single-agent 
chemotherapy. Patients were randomized 2:1 to the experimental or control arm and 
stratified by visceral disease (yes versus no), histology (triple negative breast cancer versus 
hormone-receptor positive breast cancer) and number of previous cytotoxic chemotherapy 
regimens for advanced or metastatic breast cancer (0-1 versus 2). Patients in the 
experimental arm received niraparib 300 mg (3x100 mg oral capsules) once daily on a 
continuous regimen. Patients in the control arm received physician’s choice of one of the 
following four chemotherapy regimens in 3-week cycles: eribulin, gemcitabine, 
capecitabine or vinorelbine, administered per local treatment availabilities and guidelines 
(in France, gemcitabine is not approved as a single-agent for the treatment of breast 
cancer and could therefore not be selected as a treatment option in the physician's 
choice arm). The physician’s choice chemotherapy was designated prior to 
randomization of each patient. The assigned treatment was continued until disease 
progression, unacceptable toxicity, death, patient refusal or loss to follow-up. No 
crossover to niraparib was permitted following discontinuation from physician’s choice 
treatment. Dose reductions for niraparib/physician’s choice chemotherapy were 
managed as described in the protocol.  
Trial oversight 
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This trial was conducted following the Good Clinical Practice Guidelines of the 
International Conference on Harmonization of Technical Requirements for Registration 
of Pharmaceuticals for human use (ICH-GCP)
8
 and approved by ethics review committees 
at each participating institution. All patients provided written informed consent. Trial conduct 
was supervised by an IDMC. The trial registration number (clinicaltrials.gov) is 
NCT01905592. 
The trial was conducted in collaboration with the European Organisation for Research and 
Treatment of Cancer (EORTC) and the Breast International Group (BIG), with the 
participation of BIG member Groups in different countries, as well as independent sites from 
the United States of America, Hungary, Poland, Israel, and Canada, and sponsored by 
TESARO. Data was gathered and analyzed at EORTC, and the sponsor had no access to 
the full database before the release of the results by the Steering Committee. 
Endpoints and assessments 
The primary endpoint was progression-free survival determined by blinded independent 
central review (BICR) (central-PFS) among patients with a centrally-confirmed germline 
BRCA mutation. PFS was defined as the time from randomization to objective radiologic 
progression according to RECIST version 1.1 or to death from any cause. A censoring 
scheme was prespecified according to the May 2007 FDA guidance on Clinical Trial 
Endpoint for the Approval of Cancer Drugs and Biologics9 and as shown in Table C1 in the 
April 2015 FDA guidance on Clinical Trial Endpoints for the Approval of Non-Small Cell Lung 
Cancer Drugs and Biologics10 as follows: patients were censored at randomization if no 
baseline tumor assessment was available, and patients were censored at the time of the last 
documented central independent radiologic assessment  (i) if they were alive but had no 
progression at the time of analysis, (ii) if they had discontinued treatment for any reason 
other than documented progression, (iii) if they started another anti-cancer treatment without 
evidence of progression, or (iv) if death or radiologic progression was reported after more 
than 2 consecutively missed assessments.  Tumour assessments by contrast enhanced 
computed tomography (CT) scans or/and magnetic resonance imaging (MRI), based on 
RECIST version 1.1, were conducted locally by investigators and retrospectively 
assessed by a central blinded review committee composed of two radiologists with an 
arbiter as necessary. Results of the central blinded review were used to determine the 
primary efficacy endpoint of PFS while treatment decisions were based entirely on local 
assessment. CT scans were required at screening and every 2 cycles (6 weeks) for the first 
12 months then every 3 cycles (9 weeks) until disease progression, regardless of treatment 
interruptions. If the patient discontinued prior to disease radiological progression, tumour 
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imaging continued at the specified time intervals until progression or until the start of 
subsequent anti-cancer therapy. After discontinuation of study treatment, patients were 
followed every 9 weeks for assessment of subsequent anti-cancer therapy and overall 
survival.  
Overall survival was a key secondary endpoint. Other secondary efficacy endpoints included 
PFS based on investigator assessment (local-PFS), overall response rate (defined as the 
proportion of patients achieving a best response of complete or partial response) and 
disease control rate (defined as the proportion of patients achieving a best response of 
complete or partial responses or stable disease lasting for at least 24 weeks) based on 
central review. Safety was evaluated throughout the study, and adverse events were graded 
according to the National Cancer Institute Common Terminology Criteria for Adverse Events, 
version 4.011. 
Statistical analysis 
Efficacy was assessed in the centrally-confirmed intention to treat (ITT) population 
composed of all randomized patients who had a centrally confirmed germline BRCA1/2 
mutation.  The initial overall sample size was based on the key secondary endpoint, OS, and 
on the assumption that niraparib would result in an improvement of 4 months in median OS 
from 9 to 13 months. For a true hazard ratio (HR) of 0.69, 265 deaths would provide 80% 
power at a 1-sided alpha level of 0.025. Assuming a maximum accrual rate of 10 patients 
per month,  with 40% of patients randomized on the basis of  local BRCA testing and 
assuming that 15% of those patients would then be found to be BRCA-mutation negative by 
central testing, it was estimated that a total of 324 randomized patients were required to 
obtain the necessary 306 centrally-confirmed germline BRCA mutation carrying patients in 
the OS analysis population.  Initially, the final primary PFS analysis was planned after 232 
PFS events with 99.6% power (one-sided alpha level of 0.025) to detect a difference from 3 
to 6 months in median PFS (corresponding to an HR of 0.5). The clinical relevance of the 
maximum significant HR of 0.759 that could be detected by 232 events was re-evaluated in 
the current treatment landscape. The assumptions were revised in a way that the statistically 
significant HR observed in the study is also clinically relevant. Therefore, the PFS analysis 
was redesigned to provide 80% power to detect an HR of 0.6 (equivalent to an improvement 
in median PFS from 3 to 5 months) with a one-sided alpha of 0.025, requiring approximately 
137 PFS events.  A gate-keeping strategy (i.e. sequential testing procedure) was planned to 
test for differences between treatment arms in OS only if there was evidence of a statistically 
significant improvement in PFS, to allow control of the overall type 1 error rate.  
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A futility interim analysis of the primary endpoint of PFS was planned after 93 (68%) 
centrally-confirmed PFS events, using a gamma family beta spending function with a non-
binding gamma (γ = -5) stopping boundary. Statistical design was computed using PROC 
SEQDESIGN in SAS and confirmed with EAST software. 
The primary PFS analysis was performed using a stratified log-rank test (one-sided alpha 
level = 0.025) for the difference in the distribution of PFS between niraparib and physician’s 
choice groups. Randomization factors were used as the strata for this test. A non-stratified 
log-rank test was performed to assess the robustness of the primary analysis. Hazard ratios 
and their 95% confidence interval were estimated based on a Cox proportional hazard model 
with the randomized treatment as a factor and stratified for the randomization factors. 
Additional supportive analyses were conducted in the full ITT population and in the per 
protocol populations as defined in the study protocol. Subgroup analyses of the primary 
endpoint were performed by age, geographic region, ECOG performance status, visceral 
disease, histology, number of lines of prior chemotherapy regimens for advance/metastatic 
disease, prior platinum treatment, and type of germline BRCA mutation. An exploratory 
unplanned subgroup analysis was conducted in patients with triple negative breast cancer. 
At the time of the final analysis of the primary endpoint, secondary endpoints including OS 
and PFS by investigator assessment were analysed with the same approach as for the 
primary endpoint. The overall response rate and the disease control rate were based on 
central review assessments in the subset of patients with measurable disease at baseline. 
The number and proportion of patients achieving a response are presented with their 
corresponding 95% Pearson-Clopper confidence interval.   
All safety and tolerability evaluations were conducted in the safety population, composed of 
randomized patients who received at least one dose of study medication. Adverse events 
are reported from start of treatment up to 30 days after the last treatment administration 
date. Hematology and biochemistry events were determined based on laboratory values and 
are reported from start of treatment up to the last administration of study medication. For 
some hematology and biochemistry tests, to distinguish between grade 0 and grade 1, 
normal values were required. In the case of missing normal values, CTCAE grade was 
categorized as grade 0/1. Serious adverse events are reported based on the safety 





on July 26, 2021. © 2021 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 22, 2021; DOI: 10.1158/1078-0432.CCR-21-0310 
14 
 
Between 25 February 2014 and 29 March 2017, 758 patients were registered at 106 sites in 
14 countries, of whom 215 patients were randomized: 141 patients to niraparib and 74 
patients to physician’s choice (Figure 1). Overall, 27 (12.6%) patients were subsequently 
found to be ineligible, including 9 (4.2%) patients who had not relapsed during or within 12 
months of (neo) adjuvant cytotoxic therapy in the absence of any prior cytotoxic regimens or 
chemotherapy for advanced or metastatic breast cancer. After randomization, 16 (7.4%) 
patients did not receive the assigned treatment; 7 (5.0%) in the niraparib arm, mainly due to 
ineligibility, and 9 (12.2%) in the physician’s choice arm, mainly due to patient choice, and 
were therefore excluded from the safety population (N = 199).  
Baseline characteristics were well balanced between the two treatment groups 
(Supplementary Table 1), with the exception of an apparent excess of previous platinum 
and radiotherapy use in the physician’s choice arm, with 31.1% vs. 16.3% and 71.6% vs. 
59.6%, respectively (Supplementary Table 2). At the time of clinical data cut off for the final 
analysis (1 December 2017), 8 patients were still receiving niraparib and none were still 
receiving physician’s choice. At the time of manuscript submission (December 2020), three 
patients were still on treatment with niraparib, and had been on treatment for at least 4.3 
years. The median duration of follow-up was 19.7 months in the niraparib arm and 21.4 
months in the physician’s choice arm. Baseline characteristics and prior therapies of the 
centrally-confirmed ITT population are presented in Supplementary Table 3 and 
Supplementary Table 4.  
Germline BRCA1/2 mutation was centrally confirmed in 206 (95.8%) patients: 135 in 
niraparib arm; 71 in physician’s choice arm (Table 1). Among them, 104 (50.5%) patients 
had a deleterious point mutation in BRCA1 only, 85 (41.3%) had a point mutation in BRCA2 
only, 4 (1.9%) had point mutations in both BRCA1 and BRCA2, and 13 (6.4%) had a BRCA1 
or BRCA2 large rearrangement. 
Efficacy 
Interim results 
The interim analysis was performed including all data up to 23 November 2016, with 105 
PFS events confirmed by central review assessment, a higher number of events than initially 
planned for the interim analysis (N=93). At that time, 194 patients had been randomized 
(127 to niraparib, 67 to physician’s choice).  The primary endpoint was assessed in the 185 
patients with a centrally-confirmed germline BRCA mutation (121 in niraparib arm, 64 in 
physician’s choice arm). The median duration of PFS by central review was 4.0 months in 
niraparib arm and 4.6 months in physician’s choice arm, with an HR of 1.15 (which was 
higher than the updated futility boundary of 0.884) (Figure 2A). Local assessment  of PFS 
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resulted in an HR of 0.69 (95% CI 0.46-1.02) favoring niraparib (Supplementary Figure 1), 
but the IDMC noted a high level of discordance between central and local assessments that 
resulted in a high level of informative censoring in the physician’s choice arm of the central 
assessment  (Supplementary Table 5). Based on this analysis, the IDMC advised the 
closure of recruitment into the study, effective on 29 March 2017, since the comparison 
between niraparib and the physician’s choice arms crossed the futility boundary for the 
primary endpoint,  indicating that a robust comparison of the arms would not be possible due 
to the informative censoring that occurred in the control arm. 
Final results 
The final analysis was performed including all data up to the 1 December 2017.  Among 206 
patients in the centrally-confirmed germline mutation carrier population (135 in niraparib arm, 
71 in physician’s choice arm), 135 PFS events were observed per the independent central 
review.  
The median duration of PFS by central review was 4.1 months in niraparib arm and 3.1 
months in physician’s choice arm (HR: 0.96; 95%CI: 0.65-1.44; stratified log-rank p-value: 
0.86; Figure 2B). Progression free survival as assessed by the investigator resulted in a 
median local-PFS of 5.0 months in the niraparib arm and 3.1 months in the physicians` 
choice arm (HR 0.65; 95%CI 0.46-0.93; Supplementary Figure 1). No differential benefit 
was detected in any of the pre-planned subgroup analyses (Figure 2C). Results from 
sensitivity analyses were all consistent with the primary analysis (Supplementary Table 6).  
There was substantial discordance between local and central PFS assessments 
(Supplementary Table 7). In the centrally-confirmed population, discordance in timing 
between local and central PD occurred in 64 (47.4%) patients in the niraparib arm and 35 
(49.3%) patients in physician’s choice arm. In 44 (32.6%) patients in the niraparib arm, 
discrepancies were related to earlier identification of disease progression as per central 
independent review compared to local. In contrast, in 19 (26.8%) patients in the physician’s 
choice arm, discrepancies occurred because the disease progressions reported by the local 
investigator were not confirmed by central review. In patients with discordant central and 
local PFS assessment, treatment was discontinued due to progressive disease in the 
majority of patients (57/64 patients, [89.1%] in niraparib arm and 28/35 patients [80.8%] in 
the physician’s choice arm), with toxicity reported as the main reason for discontinuation in 
only 3/64 patients (4.7%) in niraparib arm and in 1/35 patients (2.9%) in physician’s choice 
arm. 
In the centrally-confirmed ITT population, 80 (59.3%) patients in the niraparib arm and 39 
(54.9%) in the physician’s choice arm had died, resulting in a median OS of 14.5 months in 
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niraparib arm and 15.2 months in the physician’s choice arm (HR: 0.95; 95% CI: 0.63-1.42; 
stratified log-rank p-value: 0.79, Figure 3).  
Based on central assessment, 154 (74.8%) patients had measurable disease at baseline 
(106 in niraparib arm, 48 in physician’s choice arm). The overall response rate was 35% 
(95% CI: 26-45) in the niraparib arm and 31% (95% CI: 19-46) in the physician’s choice arm. 
In the exploratory unplanned analysis conducted in the subset of patients with triple negative 
breast cancer (60 patients in the niraparib arm, 23 patients in the physician’s choice arm), 
overall response rates were 32% (95% CI: 20-45) and 9% (95% CI: 1 -28), respectively 
(Table 2).  
Overall, 156/199 patients (78.4%) from the safety population were assessed for further anti-
cancer therapies, including 104 patients who had experienced disease progression per 
independent central review. After disease progression, platinum-based chemotherapy was 
initiated in 24/75 (32.0%) patients in niraparib arm and in 11/29 (37.9%) patients in 
physician’s choice arm, while 3/75 (4.0%) and 6/29 (20.7%) patients received a PARP 
inhibitor in the niraparib and physician’s choice arms, respectively.  
Safety 
Safety is summarized in Table 3, considering only the patients who received at least one 
dose of treatment (134 patients in the niraparib arm and 65 patients in the physician’s choice 
arm), and was largely consistent with prior studies of niraparib and physician’s choice 
chemotherapy.  The most common grade 3 or 4 adverse events observed with niraparib 
compared to physician’s choice chemotherapy were anaemia (45.5% versus 3.1%), 
thrombocytopenia (35.1% versus 0%), lymphopenia (22.4% vs 9.2%), neutropenia (21.6% 
versus 23.1%), and increased GGT (19.4% vs 12.3%). In the safety population, 70 (35.2%) 
patients received a blood transfusion, including 65 (48.5%) patients in the niraparib group 
and 5 (7.7%) patients in the physician’s choice group. 
Overall, 89.6% patients in the niraparib arm and 47.7% patients in the physician’s choice 
arm had a dose interruption or reduction. The most common reasons for the first dose 
interruption or reduction were hematological AEs (69.2% patients in the niraparib arm, 
35.5% patients in the physician’s choice arm), non-hematological AEs (22.5% patients in the 
niraparib arm, 48.4% patients in the physician’s choice arm), both hematologic and 
nonhematologic AEs (1.7% in the niraparib arm, none in the physician’s choice arm), and 
other reasons (6.6% patients in the niraparib arm, 16.1% patients in the physician’s choice 
arm). 
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Serious adverse events were reported in 34/141 (24.1%) patients treated with niraparib and 
in 6/74 (8.1%) patients in physician’s choice arm among the randomized patients. A fatal 
adverse event was reported in one patient in each arm. In the physician’s choice arm, one 
patient died due to sepsis before starting study treatment.  In the niraparib arm, bilateral 
pneumonia and respiratory failure were reported in one patient, but the main cause of death 
was reported by the investigator as disease progression. No cases of myelodysplastic 
syndrome or acute myeloid leukemia were reported in either arm.  
 
DISCUSSION 
The BRAVO trial was unable to accurately assess the primary objective of whether 
progression free survival was longer with niraparib than physician’s choice chemotherapy 
due to the high level of informative censoring in the physician’s choice control arm. 
Informative censoring describes a situation where censoring is unbalanced in one arm of a 
trial, affecting the interpretation of the result of that arm. Nevertheless, niraparib 
demonstrated clinical activity in patients with advanced breast cancer and germline BRCA1 
and BRCA2 mutations, as evidenced by an objective response rate of 35% in the centrally-
confirmed ITT population with measurable disease, a response rate similar to the physicians’ 
choice arm in this study, and that seen in OlympiAD12, and considerably higher than that 
seen in studies of single agent cytotoxic therapy in later line setting in metastatic breast 
cancer unselected for BRCA mutation status (such as the EMBRACE study13).  However, 
the study could not demonstrate superiority over the physician`s choice chemotherapy. In an 
exploratory analysis, niraparib had higher response rates than physician`s choice 
chemotherapy in patients with triple negative breast cancer. 
The BRAVO trial demonstrated substantial discordance between local and central review, 
with the direction of discordance being different for each study arm, possibly due to the 
open-label design of the trial. This resulted in informative censoring, where many patients 
considered to have progressed by local assessment were censored for the primary endpoint 
of PFS by central review, resulting in inflation of the centrally-determined PFS in the 
physician’s choice control arm, thus preventing robust comparison between arms. 
Acknowledging that the discordance between local and central reviews is an important issue 
in this study, on reflection, it might have been advisable to conduct central confirmation of 
progression in real-time, rather than retrospectively, as done in this study. Open-label phase 
III studies, such as BRAVO, need a robust definition of the primary endpoint when treatment 
decisions are made by local investigators and not by central review, and real-time 
adjudication could offer a way to mitigate the risk of such bias. 
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Furthermore, 12.2% patients randomized to the physician’s choice arm withdrew before 
starting treatment. The protocol had required that the primary endpoint of PFS be 
determined by independent central radiological review blinded to treatment allocation, in 
order to reduce the impact of the unblinded treatments, but despite this precaution, the 
informative censoring prevented a robust comparison of PFS between the two arms. As 
response rate is less affected by informative censoring, the secondary endpoint of response 
rate is the most robust assessment of efficacy in the BRAVO study. 
Two other randomised phase III studies of PARP inhibitors in patients with advanced breast 
cancer and germline BRCA1/2 mutations have reported, namely OlympiAD with olaparib12 
and EMBRACA with talazoparib14, both of which had overall similar designs, including 
incorporated concomitant independent central review. In the BRAVO study, the response 
rates were lower and PFS shorter, for niraparib than for olaparib in OlympiAD12 and 
talazoparib in EMBRACA14. The main explanation for this is likely differences in prior 
treatment, with patients in BRAVO having received more lines of therapy, as reflected in the 
shorter overall survival in the control arm of BRAVO. The percentage of patients enrolled in 
first line of metastatic disease was 29% in OlympiAD, 38% in EMBRACA, and 15% in 
BRAVO. In addition, per eligibility criteria, first line patients in BRAVO, but not OlympiAD nor 
EMBRACA, must have relapsed within 12 months of adjuvant chemotherapy. 
Notwithstanding these differences in patient population, there are other reasons why BRAVO 
may not have confirmed the hypothesized benefits of the use of a PARP inhibitor against an 
active comparator (physician’s choice of chemotherapy), as discussed above. Consistent 
with this, response rates of talazoparib15 and olaparib16,17 have previously been observed to 
be substantially lower in later lines of treatment. In terms of safety, most toxicity was 
hematological, mainly anemia and thrombocytopenia. In this regard, BRAVO recruited 
before the standard dose of niraparib was reduced for patients of low body weight, and this 
may have contributed to rates of hematological toxicity. 
Niraparib is approved for the maintenance treatment of platinum sensitive recurrent 
advanced ovarian cancer who have responded to prior platinum chemotherapy6. The 
BRAVO trial confirms the activity of niraparib in patients with advanced breast cancer and 
germline BRCA1 and BRCA2 mutations, with a response rate of 35%, although the response 
rate to niraparib was not higher than physician’s choice chemotherapy overall. In addition to 
these data from BRAVO, niraparib has demonstrated promising clinical efficacy in both the 
neoadjuvant treatment of participants with localized HER2−, gBRCAmut breast cancer18 as 
well as in TNBC irrespective of BRCA mutation status19. Future studies will broaden the 
search for potential benefit of PARP inhibition with niraparib in the treatment of breast 
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Table 1 Central confirmation of BRCA mutational status 
N, (%) 
Niraparib 
(N = 141) 
Physician’s choice 
(N = 74) 
Availability of gBRCAmut test prior to 
randomization 
Yes, by central lab 
Yes, by local lab 
No 




Type of central gBRCAmut found 
Point deletion in BRCA1 only 
Point deletion in BRCA2 only 
Large rearrangements 
Point deletions in BRCA1 and BRCA2 
Not done 
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Table 2 Response to treatment by central independent review in patients with 
measurable disease 
 Niraparib Physician’s choice  
 





Centrally-confirmed ITT population with measurable 
disease 
N = 106 N = 48  















Patients with triple negative breast cancer N = 60 N = 23  
Complete response (CR) 2 (3.3) 
[0.4; 11.5] 
0 - 










The analysis population was the patients from the centrally-confirmed ITT population with measurable disease at baseline. In 
the centrally-confirmed ITT population, 22 (10.7%) patients’ tumors were not assessable by central review in the absence of 
tumor assessment at baseline by central review. 95% Pearson-Clopper confidence interval; P-value based on exact Chi-square 
test. ITT: Intention To Treat; CR: Complete Response; PR: Partial response; SD: Stable Disease. 
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Table 3 Adverse events reported in ≥15 % of patients in either treatment group 
 
Niraparib (N= 134) Physician’s choice (N = 65) 
Any grade Grade 1-2 Grade ≥ 3 Any grade Grade 1-2 Grade ≥ 3 
Haematology
a
       
Anaemia 121 (90.3) 60 (44.8) 61 (45.5) 50 (76.9) 48 (73.8) 2 (3.1) 
Lymphopenia 106 (79.1) 63 (47.0) 30 (22.4) 39 (60.0) 27 (41.5) 6 (9.2) 
WBC count  104 (77.6) 89 (66.4) 15 (11.2) 46 (70.8) 35 (53.8) 11 (16.9) 
Thrombocytopenia 96 (71.6) 49 (36.6) 47 (35.1) 16 (24.6) 16 (24.6) 0 (0.0) 
Neutropenia 85 (63.4) 49 (36.6) 29 (21.6) 37 (56.9) 19 (29.2) 15 (23.1) 
Biochemistry
a
       
LDH abnormality
b
 96 (71.6)  - - 51 (78.5) - - 
GGT  79 (59.0) 53 (39.6) 26 (19.4) 35 (53.8) 27 (41.5) 8 (12.3) 
Hyperglycemia  75 (56.0) 73 (54.5) 1 (0.7) 36 (55.4) 34 (52.3) 2 (3.1) 
Alkaline phosphatase  74 (55.2) 66 (49.3) 8 (6.0) 34 (52.3) 33 (50.8) 1 (1.5) 
SGOT 63 (47.0) 62 (46.3) 1 (0.7) 35 (53.8) 35 (53.8) 0 (0.0) 
SGPT 55 (41.0) 52 (38.8) 3 (2.2) 31 (47.7) 29 (44.6) 2 (3.1) 
Hypocalcemia  35 (26.1) 34 (25.4) 1 (0.7) 8 (12.3) 8 (12.3) 0 (0.0) 
Hyponatremia 31 (23.1) 27 (20.1) 4 (3.0) 8 (12.3) 7 (10.8) 1 (1.5) 
Hypoalbuminemia  30 (22.4) 28 (20.9) 1 (0.7) 12 (18.5) 12 (18.5) 0 (0.0) 
BUN abnormality
b
  25 (18.7) - - 15 (23.1) - - 
Serum creatinine 23 (17.2) 23 (17.2) 0 (0.0) 11 (16.9) 11 (16.9) 0 (0.0) 
Other Adverse events       
Nausea  79 (59.0) 76 (56.7) 3 (2.2) 19 (29.2) 18 (27.7) 1 (1.5) 
Fatigue  73 (54.5) 62 (46.3) 11 (8.2) 34 (52.3) 30 (46.2) 4 (6.2) 
Weight loss  53 (39.6) 53 (39.6) 0 (0.0) 10 (15.4) 10 (15.4) 0 (0.0) 
Vomiting  50 (37.3) 46 (34.3) 4 (3.0) 10 (15.4) 10 (15.4) 0 (0.0) 
Constipation 49 (36.6) 48 (35.8) 1 (0.7) 11 (16.9) 11 (16.9) 0 (0.0) 
Headache 44 (32.8) 40 (29.9) 4 (3.0) 10 (15.4) 10 (15.4) 0 (0.0) 
Anorexia 41 (30.6) 39 (29.1) 2 (1.5) 7 (10.8) 6 (9.2) 1 (1.5) 
Dizziness 29 (21.6) 26 (19.4) 3 (2.2) 6 (9.2) 6 (9.2) 0 (0.0) 
Back pain 29 (21.6) 27 (20.1) 2 (1.5) 8 (12.3) 7 (10.8) 1 (1.5) 
Dyspnoea 27 (20.1) 24 (17.9) 3 (2.2) 8 (12.3) 8 (12.3) 0 (0.0) 
Insomnia  23 (17.2) 23 (17.2) 0 (0.0) 5 (7.7) 4 (6.2) 1 (1.5) 
Pain in extremity 23 (17.2) 21 (15.7) 2 (1.5) 7 (10.8) 6 (9.2) 1 (1.5) 
Mucositis oral 22 (16.4) 22 (16.4) 0 (0.0) 10 (15.4) 10 (15.4) 0 (0.0) 
Abdominal pain  22 (16.4) 19 (14.2) 3 (2.2) 13 (20.0) 11 (16.9) 2 (3.1) 
Diarrhoea 21 (15.7) 20 (14.9) 1 (0.7) 21 (32.3) 21 (32.3) 0 (0.0) 




0 (0.0) 0 (0.0) 0 (0.0) 15 (23.1) 13 (20.0) 2 (3.1) 
The analysis population was the safety population defined as all randomized patients who received at least one dose of 
treatment. Grading according to CTCAE version 4.0. 
a 
Haematology and Biochemistry abnormalities events were identified in 
the corresponding lab forms. For some haematology and biochemistry tests, to distinguish between grade 0 and grade1, 
normal values are required. In case of missing normal values, CTCAE grade was defined as grade 0/1 and these events were 
included in the “any grade” count. 
b
 Presented as “above Upper Limit of Normal”. 
Research. 
on July 26, 2021. © 2021 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 




Figure 1 Patient populations 
* Patients may be excluded from the per protocol population for several reasons. 
gBRCAmut: germline BRCA mutation; ITT: Intention To Treat. 
 
Figure 2 Progression-free survival by central independent review  
(A). Data cut off for interim analysis was 23 November 2016. The analysis population was 
the centrally confirmed ITT population (N = 185). The futility boundary was HR = 0.884. 
These results were assessed by an IDMC. (B) Data cut off for the final analysis was 01 
December 2017. (C). Subgroup analysis of progression-free survival by central review at 
final analysis. Data cut off for the final analysis was 01 December 2017. The analysis 
population was the centrally confirmed ITT population (N = 206). PFS: Progression-Free 
Survival; ITT: Intention To Treat; IDMC: Independent Data Monitoring Committee; HR: 
Hazard Ratio; CI: Confidence Interval. 
 
Figure 3 Overall survival at final analysis 
Data cut off for final analysis was 01 December 2017. The analysis population was the 
centrally confirmed ITT population (N = 206). ITT: Intention To Treat; HR: Hazard Ratio; CI: 
Confidence Interval 
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Screening population 
N = 758 
Assessed for eligibility 
Full ITT population  
N = 215 
Randomized patients 
Excluded N = 543 
• Absence of gBRCAmut N = 463 
• Uncontrolled symptomatic brain 
metastases  N = 9 
• Withdrew consent N = 6 





Per protocol population* 
N = 172 
• Eligibility 
• gBRCAmut confirmed 
• Received at least 1 dose of allocated 
therapy 
Niraparib N = 141 
• Eligible patients  N = 126 (89.4%) 
• Ineligible patients N=    15 (10.6%) 
Niraparib N = 135 
• gBRCAmut confirmed  N = 135 (95.7%) 
• gBRCAmut not confirmed  N =     6   (4.3%) 
Niraparib N = 118 
• Eligible, gBRCAmut confirmed,  
started allocated treatment  N = 118 (83.7%) 
• Not eligible    N =   15 (10.6%) 
• gBRCAmut not confirmed  N =     6   (4.3%) 
• Never started treatment  N =     7   (5.0%) 
Niraparib N = 134 
• Started therapy N = 134 (95.0%) 
• Never started therapy N =     7   (5.0%) 
Safety population  
N=199 
Received at least 1 dose of allocated 
therapy 
Physician’s choice N = 74 
• Eligible patients  N = 62 (83.8%) 
• Ineligible patients  N = 12 (16.2%) 
Physician’s choice N = 71 
• gBRCAmut confirmed  N = 71 (95.9%) 
• gBRCAmut not confirmed  N =   3   (4.1%) 
Physician’s choice N = 54 
• Eligible, gBRCA mut confirmed, 
started allocated treatment  N = 54 (73.0%) 
• Not eligible   N = 12 (16.2%) 
• gBRCAmut not confirmed  N =   3   (4.1%) 
• Never started treatment  N =   9 (12.2%) 
Physician’s choice N = 65 
• Started therapy  N = 65 (87.8%) 
• Never started therapy  N =   9 (12.2%) 
Figure 1 
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C. Subgroup analysis of progression-free survival by central review 
Figure 2 
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Figure 3
135 127 108 85 57 44 30 18 11 6Niraparib:
71 55 49 40 32 23 15 12 5 3Physicians choice:
Patients at risk

































Stratified Logrank P-value: 0.79
0.95 (0.63-1.42)80/135Niraparib
Reference39/71Physicians choice
HR (95% CI)Events/TotalTreatment arm
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